Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

181.68 +4.24 (+2.39%)
Official Closing Price Updated: 6:30 PM EDT, May 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025
For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity. 
Via Benzinga
Jim Cramer Says Even 'Safety' Stocks Look Risky, Warns Of 'Wild Card' In Washington And Rising Treasury Yields As Reasons To Stay Away From Sure Bets
Rising bond yields and uncertain politics make 'safety' stocks less appealing, says Jim Cramer. Even Procter & Gamble and Johnson & Johnson suddenly feel shaky to the market guru. 
Via Benzinga
Topics Bonds
Exposures Debt Markets
Stay informed with the top movers within the S&P500 index on Wednesday.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Wednesday as we examine the latest happenings in today's session. 
Via Chartmill
FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases
FDA grants accelerated approval to AbbVie's Emrelis for c-Met overexpressing NSCLC; siRNA partnership with ADARx includes $335 million upfront. 
Via Benzinga
Exposures Product Safety
A Look Into AbbVie Inc's Price Over Earnings
Via Benzinga
What Does the Market Think About AbbVie?
Via Benzinga
AbbVie Gets FDA Nod For Drug To Treat Lung Cancer: Retail’s Yet To React
The company also announced a collaboration and license option agreement with ADARx Pharmaceuticals to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including... 
Via Stocktwits
Exposures Product Safety
What's going on in today's session: S&P500 movers
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Expert Outlook: AbbVie Through The Eyes Of 10 Analysts
Via Benzinga
Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including United Therapeutics (NASDAQ:UTHR) and its peers. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
AbbVie Unusual Options Activity
Via Benzinga
Congressional Trading Report: Rep. Jared Moskowitz Bought Over $27K In AbbVie Stock
Via Benzinga
Top S&P500 movers in Monday's pre-market session
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. 
Via Chartmill
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices. 
Via Investor's Business Daily
Topics Government Stocks
Exposures Political US Equities
Wall Street Rips Higher As Tariff Truce Halts US–China Economic Escalation
US-China agree to slash tariffs by over 100%, easing fears of economic slowdown and inflation. Markets cheer with futures rising and yields up. 
Via Benzinga
Topics Economy World Trade
Exposures Interest Rates Tariff
Recession Worries? Here's 1 of the Best Dividend Stocks for Turbulent Times
Via The Motley Fool
Topics Economy World Trade
Exposures Economy Tariff
2 High-Yield Dividend Stocks to Buy in May and Hold Forever
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Recent Report Shows That Rep. Jefferson Shreve Bought Up to $4.75M Worth of Apple Stock
Via Benzinga
Thursday's session: gap up and gap down stock in the S&P500 index
Curious about the market action on Thursday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks
Let’s dig into the relative performance of AbbVie (NYSE:ABBV) and its peers as we unravel the now-completed Q1 therapeutics earnings season. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
This House of Representative Just Bought Up To $915K In AbbVie Stock
Via Benzinga
Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security Concerns
President Donald Trump signed an executive order Monday directing the FDA to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to announce new... 
Via Benzinga
Topics Government World Trade
Exposures Political Product Safety Tariff
Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought
Marjorie Taylor Greene disclosed buying more than 50 stocks in early May. A look at the list and why the congresswoman's past trades have drawn red flags. 
Via Benzinga
1 Mega-Cap Stock Worth Your Attention and 2 to Keep Off Your Radar
"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their... 
Via StockStory
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?
FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple chronic inflammatory diseases. 
Via Benzinga
Exposures Product Safety
Here Are All the Dividend Kings Beating the S&P 500 in 2025 -- and the 2 That Are the Best Stocks to Buy Now
Via The Motley Fool
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash?
Via The Motley Fool
Topics Earnings Economy Government
Exposures Financial Political Supply Chain
Invest in These ETFs to Prepare Your Portfolio for a Recession
Being prepared is important 
Via The Motley Fool
Topics ETFs Economy
Exposures Economy
Benzinga Bulls And Bears: Lilly, Microsoft, Starbucks — And Markets Fully Recover Tariff Chaos Losses
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.